Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD34+ hematopoietic stem cells (Stanford University)
- Development stage
- Unknown
- Lead developer
- Stanford University
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
CD34+ hematopoietic stem cells (HSCs) are multipotent progenitor cells used in the treatment of high-risk non-Hodgkin lymphoma (NHL). In the specific protocol developed by Stanford University, these cells are utilized in a tandem transplantation approach. Patients first undergo autologous hematopoietic stem cell transplantation (auto-HSCT) following high-dose chemotherapy to rescue the bone marrow. This is followed by a non-myeloablative allogeneic hematopoietic stem cell transplantation (allo-HSCT) using donor CD34+ cells. The allogeneic phase employs a unique conditioning regimen consisting of total lymphoid irradiation (TLI) and antithymocyte globulin (ATG), which is designed to promote donor cell engraftment and induce a graft-versus-lymphoma (GVL) effect while minimizing the risk of severe graft-versus-host disease (GVHD).
- Other names
- CD34+ cellsHematopoietic progenitor cellsPeripheral blood stem cellsPBSC
Beyond the preview
Go deeper on CD34+ hematopoietic stem cells (Stanford University).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD34+ hematopoietic stem cells (Stanford University).